Skip navigation
中文
English
DSpace
CRIS
首頁
單位
研究人員
研究成果檢索
分類瀏覽
單位
研究人員
研究成果檢索
學術出版
幫助
登入
中文
English
NTU Scholars
研究成果檢索
瀏覽 的方式: 作者
Cheng C.-Y.
或是輸入前幾個字:
跳到:
0-9
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
排序方式:
升冪
降冪
結果/頁面
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
作者/紀錄:
全部
1
5
10
15
20
25
30
35
40
45
50
顯示 65 到 70 筆資料,總共 70 筆
< 上一頁
公開日期
標題
作者
來源出版物
scopus
WOS
全文
2002
Synthesis of 1,4-dihydro-2-phenyl-4,4-bis(4-pyridinylmethyl)-2H-isoquinolin-3-one and related compounds as acetylcholine release enhancers
Lin M.-S.; LING-WEI HSIN
; Tsai H.-B.; Tsai M.-C.; Cheng C.-Y.
Chinese Pharmaceutical Journal
2
2004
Synthesis of 3-[4-acyl-2-(1-methoxy-1-methylethyl)morpholin-3-yl]- benzonitriles as novel potassium channel openers
Lin M.-S.; LING-WEI HSIN
; Cheng C.-Y.
Journal of the Chinese Chemical Society
0
2
2003
Synthesis of galanthamine analogs as acetylcholinesterase inhibitors via intramolecular heck cvclization
PI-HUI LIANG
; LING-WEI HSIN
; Pong S.-L.; Hsu C.-H.; Cheng C.-Y.
Journal of the Chinese Chemical Society
12
12
2008
A systematic classification of the congenital bronchopulmonary vascular malformations: Dysmorphogeneses of the primitive foregut system and the primitive aortic arch system
Lee M.-L.; Lue H.-C.; ING-SH CHIU
; Chiu H.-Y.; Tsao L.-Y.; Cheng C.-Y.; Yang A.D.
Yonsei Medical Journal
13
12
2017
Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up
KUAN-YIN LIN
; Cheng C.-Y.; Li C.-W.; Yang C.-J.; Tsai M.-S.; Liu C.-E.; Lee Y.-T.; Tang H.-J.; Wang N.-C.; Lin T.-Y.; Lee Y.-C.; Lin S.-P.; YU-SHAN HUANG
; Zhang J.-Y.; Ko W.-C.; Cheng S.-H.; CHIEN-CHING HUNG
; Taiwan HIV Study Group
PLoS ONE
34
32
2014
Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway
Hung T.-H.; Hsu S.-C.; Cheng C.-Y.; Choo K.-B.; Tseng C.-P.; Chen T.-C.; Lan Y.-W.; Huang T.-T.; HSIN-CHIH LAI
; Chen C.-M.; Chong K.-Y.
Oncotarget
54
55